Immunosuppressive and biologic therapy for ulcerative colitis

Expert Opinion on Emerging Drugs

Volumn 17, Issue 4, 2012, Pages 449-467

  Ardizzone, Sandro ^a,b   Cassinotti, Andrea ^a,b   De Franchis, Roberto ^a,b  

^a Cattedra e Divisione di Gatroenterologia Ed Endoscopia Digestiva   (Italy)

^b Gastroenterology Oncology Surgery   (Italy)

Author keywords

Anti TNF agents; Conventional immunosuppressants; Emerging drugs; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ALLOPURINOL; AMINOSALICYLIC ACID; ANRUKINZUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; CYCLOSPORIN A; DELMITIDE; DERSALAZINE; ETROLIZUMAB; GOLIMUMAB; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PF 547659; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; SOTRASTAURIN; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; TOFACITINIB; UNINDEXED DRUG; VEDOLIZUMAB; VIDOFLUDIMUS;

BONE MARROW SUPPRESSION; CHRONIC DISEASE; COLON RESECTION; COMPARATIVE STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HEPATITIS; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; JAUNDICE; LISTERIOSIS; MAINTENANCE THERAPY; META ANALYSIS; MICROCYTIC ANEMIA; PANCREATITIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TUBERCULOSIS; ULCERATIVE COLITIS;

AGE FACTORS; ANIMALS; COLITIS, ULCERATIVE; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; TIME FACTORS;

EID: 84870476364     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.744820     Document Type: Review

References (127)

1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713-25
2. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17
3. Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis 2004;10:848-59
4. Rutgeerts P, D'Haens G, Hiele M, et al. Appendectomy protects against ulcerative colitis. Gastroenterology 1994;106:1251-3
5. Ardizzone S, Bianchi Porro G. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med 2002;252:475-96
6. Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol 2000;95:469-73
7. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86
8. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955;ii:1041-8
9. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9
10. Stange EF, Travis SPL, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis 2008;2:1-23
11. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analyis of changes in disease activity over years. Gastroenterology 1994;107:3-11
12. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the firts 10 years of ulcerative colitis: results from a population- based inception cohort (IBSEN study). Scand J Gastroenterol 2009;44:431-40
13. Bianchi Porro G, Cassinotti A, Ferrara E, et al. Review article: the management of steroid-dependency in ulcerative colitis. Aliment Pharmacol Ther 2007;26:779-94
14. Gore RM. Characteristic morphologic changes in chronic ulcerative colitis. Abdom Imaging 1995;20:275-7
15. Torres J, Billioud V, Peyrin-Biroulet L, et al. Ulcerative colitis as a sole mucosal disease: another misunderstanding? Gut 2012;61:633
16. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35
17. Hanauer SB, Preent DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003;3:81-92
18. Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rv Clin Pharmacol 2012;5:113-23
19. Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology 2011;140:1827-37; e2
20. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60
21. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011;9:483-489.e3
22. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-9
23. Ardizzone S, Maconi G, Russo A, et al. Randomized controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53
24. Timmer A, McDonald JW, McDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;1:CD000478
25. Gisbert JP, Linares PM, Mcnicholl AG, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009;30:126-37
26. Khan KJ, Dubinsk MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:630-42
27. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in pateints receiving thiopurines for inflammatory bowel: a prospective observational cohort study. Lancet 2009;374:1617-25
28. De Miranda P, Beacham LM, Creagh TH, et al. The metabolic fate of the methylnitroimidazole moiety of azathioprine in the rat. J Pharmacol Exp Ther 1973;187:588-601
29. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-39
30. Weinshilboum RN, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase acitivty. Am J Hum Genet 1980;32:651-62
31. Dubinsky MC, Lamothe S, Ying Yang H, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13
32. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acuteazathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54
33. Sandborn WJ. Azathioprine/6- mercaptopurine: mechanism of action, pharmacology and toxicity. In: Fellerman K, Jewell DP, Sandborn WJ, Schlmerich J, Stange EF, editors. Immunosuppression in inflammatory bowel diseases. Standards, new developments, future trends. Falk Symposium 119. Kluwer Academic Publishers; Dordrecht (NL): 2001. p. 91-100
34. Booth RA, Ansari MT, Loit E, et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011;154:814-23
35. Roblin X, Oussalah A, Chevaux JB, et al. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts. Inflamm Bowel Dis 2011;17:2480-7
36. Witte TN, Ginsberg AL. Use of allopurinol with low-dose 6- mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Can J Gastroenterol 2008;22:181-5
37. Govani SM, Higgins PDR. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis 2010;4:444-9
38. Smith MA, Blaker P, Marinaki AM, et al. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis 2012;6:905-12
39. Chande N, MacDonald JW, McDonald JK, et al. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;4:CD006618
40. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-21
41. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005;1:CD004277
42. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-31
43. Arts J, D'Haens G, Zeegers M. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;1:73-8
44. Ogata H, Matsui T, Nakamura M, et al. A randomized dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-62
45. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
46. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-60
47. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long- term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201
48. Panaccione R, Ghosh S, Middleton S, et al. Infliximab, Azathioprine, or Infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial. DDW; 7 - 10 May, 2011; Chicago, IL, USA
49. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11
50. Laharie D, Bourreille A, Branche J, et al. Cyclosporin versus Infliximab in severe acute ulcerative colitis refractory to intravenous steroids: a randomized trial. Lancet 2012;pii; S0140-6736 (12)61084-8
51. Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008;6:1112-16
52. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial. Gut 2011;60:780-7
53. Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;42:257-65
54. Gisbert JP, González-Lama Y, Maté J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007;25:19-37
55. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006(3):CD005112
56. Huang X, Lv B, Jin HF, Zhang S. A meta-analysis of the therapeutic effects of tumor necrosis factor-a blockers on ulcerative colitis. Eur J Clin Pharmacol 2011;67:759-66
57. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59
58. Cohen R, Yu A, Wu E, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010;31:693-707
59. Holtmann MH, Galle PR. Current concept of pathophysiological understanding and natural course of ulcerative colitis. Langenbecks Arch Surg 2004;389:341-9
60. Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol 2008;14(43):6641-7
61. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997;32:1134-9
62. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006;131:719-28
63. Buchanan J, Wordsworth S, Ahmad T, et al. Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers. JCC 2011;5:301-16
64. Higgins P, Rubin D, Kaulback K, et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009;29:247-57
65. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992;14:309-17
66. Tsai HH, Punekar Y, Morris J, et al. A model of the long-term costeffectiveness of scheduled maintenance treatment with infliximab for moderate to severe ulcerative colitis. Aliment Pharmacol Ther 2008;28:1230-9
67. Xie F, Blackhouse G, Assasi N, et al. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc 2009;7:20
68. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902
69. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7
70. Lichtenstein G, Cohen R, Feagan B, et al. Safety of infliximab and other Crohn's disease therapies: TREAT registry data with 24575 patient-years of follow-up. Am J Gastroenterol 2008;103:S436
71. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-36
72. Cassinotti A, Actis G, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009;104:2760-7
73. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52
74. Kandiel A, Fraser AG, Korrelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:112-15
75. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24
76. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination antitumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81
77. D'Haens G, Panaccione R, Higgins P, et al. The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106:199-212
78. Travis S, Feagan B, Rutgeerts P, et al. The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy. J Crohns Colitis 2012;6S2:S250-9
79. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2011;9:483-9
80. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100:1345-53
81. van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012;61:235-40
82. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012;61:918-32
83. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize and atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7
84. Monteleone I, Vavassori P, Biancone L, et al. Immunoregulation in the gut: success and failures in human disease. Gut 2002;50:iii60-4
85. Danese S, Semerraro S, Marini M, et al. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig Liver Dis 2005;37:811-18
86. Somerville L, Krynetski EY, Krynetskaia NF, et al. Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem 2003;278:1005-11
87. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996;273:1109-11
88. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activa tion is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-45
89. Poppe D, Tiede I, Fritz G, et al. Azathioprine suppresses ezrin-radixinmoesin- dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006;176(1):640-51
90. Creed TJ, Probert CS, Norman MN, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. APT 2006;23:1435-42
91. Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a humanized monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomized, double-blind, placebo controlled, dose ranging trial. Gut 2006;55:1568-74
92. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550e64
93. Mannon PJ, Hornung RL, Yang Z, et al. Suppression of inflammation in ulcerative colitis by interferon-b-1a is accompanied by inhibition of IL-13 production. Gut 2011;60:449e55
94. Ajdukovic J, Tonkic A, Salamunic I, et al. Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative colitis. Hepatogastroenterology 2010;57:1442-4
95. Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 2009;58:1629-36
96. Fitzpatrick LR. Novel pharmacological approaches for inflammatory bowel disease: targeting key intracellular pathways and the IL-23/IL-17 axis. Int J Inflam 2012;2012:389-404
97. Ghoreschi K, Laurence A, ÓShea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273e87
98. Ghoreschi K, Jesson MI, Lee JL, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP- 690,550). J Immunol 2011;186:4234e43
99. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-24
100. Vincenti F, Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune disease and transplantation. Annu Rev Med 2007;58:347e58
101. Plevy S, Salzberg B, Van Assche G, et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 2007;133:1414e22
102. Baumgart DC, Targan SR, Dignass AU, et al. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2010;16:620e9
103. Leiper K, Martin K, Ellis A, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011;60:1520e6
104. Hanauer SB, Sandborn WJ, Sands BE, et al. DDW 2010 649: a randomized placebo-controlled trial of abatacept for moderately-to-severely active Crohn's disease (CD). Gastroenterology 2010;138(Suppl 1):S-86
105. Sandborn WJ, Colombel JF, Sands BE, et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012;143:62-9
106. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993;11:767e804
107. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11e25
108. Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Ther Adv Gastroenterol 2010;3:239e58
109. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499e507
110. Miner PB, Geary RS, Matson J, et al. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther 2006;23:1427e34
111. van Deventer SJ, Wedel MK, Baker BF, et al. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006;23:1415e25
112. Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 2011;60:1068e75
113. Cassinotti A, Annaloro C, Ardizzone S, et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 2008;57:211-17
114. Clerici M, Cassinotti A, Onida F, et al. Immunomodulatory effects of unselected haematopoietic stem cells autrotransplantation in refractory Crohn's disease. Dig Liver Dis 2011;43:946-52
115. Burt RK, Craig RM, Milanetti F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 2010;116:6123-32
116. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a pahse I study. Gut 2010;59:1662-9
117. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008;2:219-25
118. Froslie K.F, Jahnsen J, Moum B.A, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-22
119. Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011;5:477-83
120. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9
121. Beaugerie L, Seksik P, Carrat F. Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with longstanding extensive colitis: the CESAME prospective data [abstract]. J Crohn's Colitis 2009;3:S5
122. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the longterm efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8
123. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-31
124. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33
125. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
126. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;62:1383-95
127. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7